Clinuvel

Clinhope

Well-known member
Anybody have some design skills? And could help with a logo above where you see "S h a r e T e a s e"
I’d be happy to help, i have some design skills and have Illustrator but after my effort with the last Clinuvel logo on SS rightly got the applause of crickets, and PADs design was bang on so i think all i can do is help.
Any ideas of what the logo is?
 

PortugueseMan

Well-known member
ITALY

One more order added to the list:

[January 17] Sudtirol Health Authority - 66.525,00 AUD
[2020] Sudtirol Health Authority - 304.660,00 AUD
[March 18] Padua University Hospital - 871.880,00 AUD
[April 3] Padua Hospital - 661.480,00 AUD (this file will be deleted from the Smallpdf website on July 15, 2020, so I uploaded it here as an attachment to this post)
[April 24] Brescia Civil Hospital - 951.105,00 AUD
[April 30] University Hospital Giuliano Isontina - 70.300,00 AUD
[June 16] Maggiore Policlinico Hospital - 1.725.545,00 AUD
 

Attachments

Last edited:

schlitzo

Well-known member
What a way to promote your company. By locking it off so no one can see it unless you're approved by Clinuvel. Bizarre.
You can can there by this - https://www.clinuvel.com/investors/analyst-coverage
Outstanding Analyst Coverage. The latest being 2018, then goes back to 2013! WTF! if you're going to do something like this, why not professionally and with the latest reports? Clinuvel really needs someone there to cover all bases, so this kind of thing doesn't happen. Any interested investor would take one look at this (for 5 secs) and move on.
 

Johnny H

Well-known member
So from just one quarter (April-Jun) in Italy, we have about $3.35 million AUD in revenue. Not bad... Not bad at all.


ITALY

One more order added to the list:

[January 17] Sudtirol Health Authority - 66.525,00 AUD
[2020] Sudtirol Health Authority - 304.660,00 AUD
[March 18] Padua University Hospital - 871.880,00 AUD
[April 3] Padua Hospital - 661.480,00 AUD (this file will be deleted from the Smallpdf website on July 15, 2020, so I uploaded it here as an attachment to this post)
[April 24] Brescia Civil Hospital - 951.105,00 AUD
[April 30] University Hospital Giuliano Isontina - 70.300,00 AUD
[June 16] Maggiore Policlinico Hospital - 1.725.545,00 AUD
 

schlitzo

Well-known member
I’d be happy to help, i have some design skills and have Illustrator but after my effort with the last Clinuvel logo on SS rightly got the applause of crickets, and PADs design was bang on so i think all i can do is help.
Any ideas of what the logo is?
I've got some ideas - how about something like this? Hang on, are we live now??? -
1593645630854.png
 

g. ruqt

Member
Greetings All,

Long time Sharecafe follower. Longer time follower of the "Barbie" drug, Melanotan, (years of pre cursors and post cursing).
I don't recall posts on some of the Afamelanotide medical research studies referenced in the Pub Med medical article free access database such as 2018 and 209 articles listing Afamelanotide as a "promising treatment" for acne vulgaris. A mystery why such studies remain unexplored by Clinuvel.


From pathogenesis of acne vulgaris to anti-acne agents. Arch Dermatol Res. 2019;311(5):337-349. doi:10.1007/s00403-019-01908-x

Afamelanotide in the Treatment of Dermatologic Disease. Skin Therapy Lett. 2018;23(6):6-10. (listing acne)


https://pubmed.ncbi.nlm.nih.gov/

(PubMed Search function can be used to search keyword, studies, authors, etc. sortable by date or relevance.)

Cheers
 

johnnytech

Moderator
Staff member
Just noticed that SC deleted my post about the European rollout...
It might be archived here on ST. If you can't find it, let me know the approximate date... I took a lot of screenshots of SC as soon as we saw they were deleting posts. I remember going back a fair bit. Shoot me a PM.
 

stmccallum

Active member
Just noticed that SC deleted my post about the European rollout... That post had only information in the public domain, most of it provided directly by several European health agencies (still have the emails, just in case...). It seems that Lachlan Hay didn't like that I called him a liar...
Oh, you were poking the bear.... and he swatted you down, not the way things should run sadly, and unfortunately share performance falters while he spends time on non-critical items.
 

seeva222

Well-known member
So, I'm on the research version of Scenesse for my Vitiligo
Everything is spotting even my thumbs. I stopped for awhile just because I turned too dark. One weird observation. I have a melasma on my face that has shrunk by 2/3rds? I have no idea if this is related.
 

investek

Well-known member
Just noticed that SC deleted my post about the European rollout... That post had only information in the public domain, most of it provided directly by several European health agencies (still have the emails, just in case...). It seems that Lachlan Hay didn't like that I called him a liar...
Hi everyone, big thanks to JT and Mr Dax for getting this set up.

PM, I took a copy of your post, see below, thinking it may get deleted, hopefully the links stayed intact.

To date, more than a dozen European countries have made Scenesse available as standard of care to EPP patients, including Germany and the Netherlands, Hay said.

I'm quoting a PUBLIC statement from Lachlan Hay, the General Manager of Clinuvel's European office (just in case...). After thoroughly investigating this matter for several weeks, I can now confirm that Lachlan Hay LIED to the media and, consequently, to readers (which includes EPP patients and CUV shareholders).

To prevent that gentleman from trying to delete this post on the grounds that I am making a false accusation, I will provide evidence of my statement.

So let's go in parts.

1. Lachlan Hay said that "more than a dozen European countries have made Scenesse available as standard of care to EPP patients". More than a dozen is at least 13.
2. European countries where we know for sure that Scenesse has been made available (through National Health System or Private Insurance Companies) are six: Germany, The Netherlands, Austria, Italy, Switzerland and Slovenia. I will add another country, Poland, to the list, although I have not found any effective proof that Scenesse has actually made been available in there. So seven countries in total.
3. Scenesse was approved in Europe by the EMA, so the European marketing authorization only covers the European countries of the European Economic Area, in a total of 32 (27 EU members, 3 EFTA members, Switzerland and UK).
4. If we remove from the group of the 32 EEA countries the seven countries that made Scenesse available, we are left with 25 countries, namely: Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Greece, Hungary, Ireland, Latvia, Lithuania, Luxembourg, Malta, Portugal, Romania, Slovakia, Spain, Sweden, Iceland, Liechtenstein, Norway and UK.
5. Of those 25 countries, 21 did not made Scenesse available:
  • Belgium (NOT AVAILABLE - list updated some days ago: Scenesse is written in black, which means "not commercialised")
  • Bulgaria (NOT AVAILABLE)
  • Croatia (NOT AVAILABLE - confirmed by email by the Croatian Agency for Medicinal Products)
  • Czech Republic (NOT AVAILABLE – confirmed by email by the Czech State Institute for Drug Control)
  • Denmark (NOT AVAILABLE - under review)
  • Estonia (NOT AVAILABLE - confirmed by email by the Estonian Department of Marketing Authorisations)
  • Finland (NOT AVAILABLE – confirmed by email by the Finnish Medicines Agency Fimea)
  • France (not yet approved, final decision in the next few days)
  • Greece (NOT AVAILABLE; not on the list of reimbursed drugs)
  • Hungary (NOT AVAILABLE - confirmed by email by the Hungarian National Institute of Pharmacy and Nutrition)
  • Ireland (NOT AVAILABLE; not on the list of reimbursed drugs)
  • Latvia (NOT AVAILABLE - confirmed by email by the Latvian Department of Information on Medicines Distribution)
  • Liechtenstein (NOT AVAILABLE – confirmed by email by the Liechtenstein Health Office)
  • Lithuania (NOT AVAILABLE; not on the list of reimbursed drugs)
  • Portugal (my country, Scenesse is NOT AVAILABLE here)
  • Romania (NOT AVAILABLE - confirmed by email by the Romanian National Agency for Medicines)
  • Slovakia (NOT AVAILABLE – confirmed by email by the Slovak State Institute for Drug Control)
  • Spain (REJECTED)
  • Sweden (NOT AVAILABLE - under review; someone from the Swedish porphyria patient organisation confirmed to me that Scenesse is still not available in Sweden)
  • Norway (REJECTED)
  • UK (APPEALLED; still waiting for a final decision)
6. I was unable to confirm the state of the situation in Cyprus, Malta, Iceland and Luxembourg. However, I have serious doubts that Scenesse is available in these countries: we are talking of very small countries and of a relatively insignificant market for Clinuvel.

I confess that I was very impressed with the availability of several European agencies to provide the information I requested. More: some of them were somehow surprised by the fact that Clinuvel never submitted a reimbursement dossier for a drug that received a marketing authorization in 2014…

Another piece of information for Mr. Hay: in order to obtain all this information, I did not have to pretend to be someone I was not. I wrote to the European agencies through my personal email and introduced myself as a Portuguese citizen. I did not do anything illegal or illegitimate, on the contrary! I exercised a right that European Union laws offer me: the right to transparency.

In view of all this, I only have one question: why did Lachlan Hay lie about the availability of Scenesse in Europe? I'm deeply offended by this unethical behavior.
 

CUV Quote (Yesterday's close)

Time: 4:10PM AEDT
Price: 39.19
Volume: 69444
Top